Monomelic Amyotrophy
Information Page |
NINDS is part of the
National Institutes of
Health
Table of Contents (click to jump to sections)
What is Monomelic Amyotrophy?
Is there any treatment?
What is the prognosis?
What research is being done?
What is Monomelic Amyotrophy?
Monomelic amyotrophy (MMA) is characterized by progressive degeneration and loss of motor neurons, the nerve cells in the
brain and spinal cord that are responsible for controlling voluntary muscles. It is characterized by weakness and wasting
in a single limb, usually an arm and hand rather than a foot and leg. There is no pain associated with MMA. While some physicians
contend that mild sensory loss may be associated with this disease, many experts suggest that such symptoms actually indicate
a cause other than MMA. MMA occurs in males between the ages of 15 and 25. Onset and progression are slow. MMA is seen most
frequently in Asia, particularly in Japan and India; it is much less common in North America. In most cases, the cause is
unknown, although there have been a few published reports linking MMA to traumatic or radiation injury. There are also familial
forms of MMA. Diagnosis is made by physical exam and medical history. Electromyography (EMG), a special recording technique
that detects electrical activity in muscles, shows a loss of the nerve supply, or denervation, in the affected limb; MRI and
CT scans may show muscle atrophy. People believed to have MMA should be followed by a neuromuscular disease specialist for
a number of months to make certain that no signs of other motor neuron diseases develop.
Is there any treatment?
What is the prognosis?
What research is being done?
Select this link to view a list of studies currently seeking patients.
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated February 13, 2007